Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate

Journal of Steroid Biochemistry and Molecular Biology

Volumn 163, Issue , 2016, Pages 121-128

  Hashimoto, Mari ^a   Kobayashi, Kaoru ^a   Yamazaki, Mana ^a   Kazuki, Yasuhiro ^b,c   Takehara, Shoko ^c   Oshimura, Mitsuo ^c   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Cholesterol; CYP3A; Cytochrome P450; Prostate; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CHOLESTEROL; CYTOCHROME P450 3A; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TESTOSTERONE; 6 BETA-HYDROXYTESTOSTERONE; AR PROTEIN, MOUSE; CYP3A PROTEIN, MOUSE; CYTOCHROME P450; MEMBRANE PROTEIN; PROTEIN BINDING; SIGNAL PEPTIDE; SREBF2 PROTEIN, MOUSE; SREBP CLEAVAGE-ACTIVATING PROTEIN; TESTOSTERONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE TARGETING; HYDROXYLATION; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TESTOSTERONE BLOOD LEVEL; ANIMAL; BINDING SITE; DEFICIENCY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BINDING SITES; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION; HYDROXYTESTOSTERONES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; PROMOTER REGIONS, GENETIC; PROSTATE; PROTEIN BINDING; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TESTOSTERONE;

EID: 84975461627     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.04.018     Document Type: Article

References (37)

1. [1] Anderson, D.C., Sex-hormone-binding globulin. Clin. Endocrinol. (Oxf.) 3:1 (1974), 69–96.
2. [2] Sar, M., Lubahn, D.B., French, F.S., Wilson, E.M., Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127:6 (1990), 3180–3186.
3. [3] Mäenpää, J., Pelkonen, O., Cresteil, T., Rane, A., The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J. Steroid Biochem. Mol. Biol. 44 (1993), 61–67.
4. [4] Sapone, A., Affatato, A., Canistro, D., Broccoli, M., Trespidi, S., Pozzetti, L., Biagi, G.L., Cantelli-Forti, G., Paolini, M., Induction and suppression of cytochrome P450 isoenzymes and generation of oxygen radicals by procymidone in liver, kidney and lung of CD1 mice. Mutat. Res. 527:1–2 (2003), 67–80.
5. [5] Draper, A.J., Madan, A., Smith, K., Parkinson, A., Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes. Drug Metab. Dispos. 26:4 (1998), 299–304.
6. [6] Waxman, D.J., Attisano, C., Guengerich, F.P., Lapenson, D.P., Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263:2 (1988), 424–436.
7. [7] Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T.B., Ingelman-Sundberg, M., Oscarson, M., Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281:5 (2001), 1349–1355.
8. [8] Finnström, N., Bjelfman, C., Söderström, T.G., Smith, G., Egevad, L., Norlén, B.J., Wolf, C.R., Rane, A., Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Investig. 31:10 (2001), 880–886.
9. [9] Stamey, T.A., Warrington, J.A., Caldwell, M.C., Chen, Z., Fan, Z., Mahadevappa, M., McNeal, J.E., Nolley, R., Zhang, Z., Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J. Urol. 166:6 (2001), 2171–2177.
10. [10] Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., Wojnowski, L., Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30:10 (2002), 1108–1114.
11. [11] Zhang, B., Cheng, Q., Ou, Z., Lee, J.H., Xu, M., Kochhar, U., Ren, S., Huang, M., Pflug, B.R., Xie, W., Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 151:12 (2010), 5721–5729.
12. [12] Swinnen, J.V., Ulrix, W., Heyns, W., Verhoeven, G., Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 12975–12980.
13. [13] Heemers, H., Verrijdt, G., Organe, S., Claessens, F., Heyns, W., Verhoeven, G., Swinnen, J.V., Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. J. Biol. Chem. 279:29 (2004), 30880–30887.
14. [14] Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109:9 (2002), 1125–1131.
15. [15] Kazuki, Y., Kobayashi, K., Aueviriyavit, S., Oshima, T., Kuroiwa, Y., Tsukazaki, Y., Senda, N., Kawakami, H., Ohtsuki, S., Abe, S., Takiguchi, M., Hoshiya, H., Kajitani, N., Takehara, S., Kubo, K., Terasaki, T., Chiba, K., Tomizuka, K., Oshimura, M., Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum. Mol. Genet. 22:3 (2013), 578–592.
16. [16] Hashimoto, M., Kobayashi, K., Watanabe, M., Kazuki, Y., Takehara, S., Inaba, A., Nitta, S., Senda, N., Oshimura, M., Chiba, K., Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J. Lipid Res. 54:8 (2013), 2060–2068.
17. [17] Yoshimoto, K., Echizen, H., Chiba, K., Tani, M., Ishizaki, T., Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 39:4 (1995), 421–431.
18. [18] Pirke, K.M., Geiss, M., Sintermann, R., A quantitative study on feedback control of LH by testosterone in young adult and old male rats. Acta Endocrinol. 89 (1978), 789–795.
19. [19] Jariwala, U., Prescott, J., Jia, L., Barski, A., Pregizer, S., Cogan, J.P., Arasheben, A., Tilley, W.D., Scher, H.I., Gerald, W.L., Buchanan, G., Coetzee, G.A., Frenkel, B., Identification of novel androgen receptor target genes in prostate cancer. Mol. Cancer, 6, 2007, 39.
20. [20] Viennois, E., Esposito, T., Dufour, J., Pommier, A., Fabre, S., Kemeny, J.L., Guy, L., Morel, L., Lobaccaro, J.M., Baron, S., Lxrα regulates the androgen response in prostate epithelium. Endocrinology 153:7 (2012), 3211–3223.
21. [21] Fradet, Y., Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev. Anticancer Ther. 4:1 (2004), 37–48.
22. [22] van Herwaarden, A.E., Wagenaar, E., van der Kruijssen, C.M., van Waterschoot, R.A., Smit, J.W., Song, J.Y., van der Valk, M.A., van Tellingen, O., van der Hoorn, J.W., Rosing, H., Beijnen, J.H., Schinkel, A.H., Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Investig. 117:11 (2007), 3583–3592.
23. [23] You, L., Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chem. Biol. Interact. 147:3 (2004), 233–246.
24. [24] Yang, T., Goldstein, J.L., Brown, M.S., Overexpression of membrane domain of SCAP prevents sterols from inhibiting SCAP·SREBP exit from endoplasmic reticulum. J. Biol. Chem. 275:38 (2000), 29881–29886.
25. [25] Seoa, Y.K., Zhub, B., Jeona, T.I., Osbornea, T.F., Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. Exp. Cell Res. 315:18 (2009), 3113–3139.
26. [26] Adams, C.M., Reitz, J., De Brabander, J.K., Feramisco, J.D., Li, L., Brown, M.S., Goldstein, J.L., Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J. Biol. Chem. 279:50 (2004), 52772–52780.
27. [27] Rannikko, S., Adlercreutz, H., Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 4:3 (1983), 223–229.
28. [28] Gann, P.H., Hennekens, C.H., Ma, J., Longcope, C., Stampfer, M.J., Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst. 88:16 (1996), 1118–1126.
29. [29] Solomon, K.R., Freeman, M.R., The complex interplay between cholesterol and prostate malignancy. Urol. Clin. N. Am. 38:3 (2011), 243–259.
30. [30] Pelton, K., Freeman, M.R., Solomon, K.R., Cholesterol and prostate cancer. Curr. Opin. Pharmacol. 12:6 (2012), 751–759.
31. [31] Platz, E.A., Leitzmann, M.F., Visvanathan, K., Rimm, E.B., Stampfer, M.J., Willett, W.C., Giovannucci, E., Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 98:24 (2006), 1819–1825.
32. [32] Murtola, T.J., Tammela, T.L., Lahtela, J., Auvinen, A., Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomark. Prev. 16:11 (2007), 2226–2232.
33. [33] Lamba, J.K., Lin, Y.S., Schuetz, E.G., Thummel, K.E., Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54:10 (2002), 1271–1294.
34. [34] Werk, A.N., Cascorbi, I., Functional gene variants of CYP3A4. Clin. Pharmacol. Ther. 96:3 (2014), 340–348.
35. [35] Werk, A.N., Lefeldt, S., Bruckmueller, H., Hemmrich-Stanisak, G., Franke, A., Roos, M., Küchle, C., Steubl, D., Schmaderer, C., Bräsen, J.H., Heemann, U., Cascorbi, I., Renders, L., Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin. Pharmacol. Ther. 95:4 (2014), 416–422.
36. [36] Thummel, K.E., Wilkinson, G.R., In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38 (1998), 389–430.
37. [37] Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., McLeod, H.L., Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44:3 (2005), 279–304.